The link between the expression or overexpression of PD-L1 (the ligand of PD-1) and the efficacy of anti-HER2 antibodies in some patients [37,38,39] led to the testing of the combination of tumor-targeting mAbs (TTmAbs), for instance against HER family members, and of antibodies against ICMs in some cancers. Here, ERBB2 is linked to neoplasm.